The Mechanism and Management of Adverse Cardiac Reactions Induced by Immune Checkpoint Inhibitors Therapy.

IF 1.8 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiology Research and Practice Pub Date : 2020-12-16 eCollection Date: 2020-01-01 DOI:10.1155/2020/8367651

Fangning Rong, Kangting Ji, Yingpei Weng, Yangpei Peng

引用次数: 0

Abstract

Immune checkpoint inhibitors (ICIs) therapy has recently been introduced to all kinds of cancers. The adverse reactions associated with this therapy have attracted much attention. The heart-related adverse reactions are mainly the immune-related myocarditis and heart failure. Cases of adverse cardiac reactions caused by ICIs therapy have been clearly reported. However, the pathogenesis of the adverse cardiac reactions remains unclear. Therefore, this article briefly reviews the mechanism and management of adverse cardiac reactions caused by ICIs therapy.

查看原文本刊更多论文

免疫检查点抑制剂治疗引起心脏不良反应的机制和处理。

免疫检查点抑制剂(ICIs)疗法最近被引入到各种癌症中。与该疗法相关的不良反应引起了人们的广泛关注。心脏相关不良反应主要是免疫相关性心肌炎和心力衰竭。已明确报道了由ICIs治疗引起的心脏不良反应。然而，心脏不良反应的发病机制尚不清楚。因此，本文就ICIs治疗引起心脏不良反应的机制及处理作一综述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiology Research and Practice Medicine-Cardiology and Cardiovascular Medicine

CiteScore

4.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Cardiology Research and Practice is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies that focus on the diagnosis and treatment of cardiovascular disease. The journal welcomes submissions related to systemic hypertension, arrhythmia, congestive heart failure, valvular heart disease, vascular disease, congenital heart disease, and cardiomyopathy.